A detailed history of Us Bancorp \De\ transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 860 shares of TSHA stock, worth $1,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares
860
Previous 16,077 94.65%
Holding current value
$1,591
Previous $36,000 97.22%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$2.01 - $2.46 $30,586 - $37,433
-15,217 Reduced 94.65%
860 $1,000
Q2 2024

Aug 06, 2024

SELL
$2.04 - $4.17 $3,184 - $6,509
-1,561 Reduced 8.85%
16,077 $36,000
Q1 2024

May 07, 2024

BUY
$1.43 - $3.25 $25,222 - $57,323
17,638 New
17,638 $50,000
Q1 2022

May 11, 2022

SELL
$5.22 - $11.86 $2,735 - $6,214
-524 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$11.43 - $19.2 $5,989 - $10,060
524 New
524 $6,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $89.5M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.